Caisse de depot et placement du Quebec Makes New Investment in Kenvue Inc. $KVUE

Caisse de depot et placement du Quebec acquired a new stake in Kenvue Inc. (NYSE:KVUE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 844,651 shares of the company’s stock, valued at approximately $16,141,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of KVUE. Johnson Financial Group Inc. acquired a new stake in Kenvue in the 2nd quarter valued at $26,000. CoreCap Advisors LLC increased its stake in Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after purchasing an additional 591 shares in the last quarter. Elyxium Wealth LLC acquired a new position in Kenvue during the fourth quarter worth $26,000. MV Capital Management Inc. acquired a new position in Kenvue during the fourth quarter worth $28,000. Finally, Bell Investment Advisors Inc bought a new position in shares of Kenvue in the second quarter valued at $35,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KVUE. Barclays lifted their price objective on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. Weiss Ratings raised shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. UBS Group decreased their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen lowered Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Three research analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $19.27.

Kenvue Stock Performance

KVUE stock opened at $19.15 on Friday. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. The firm has a market cap of $36.78 billion, a PE ratio of 22.01, a P/E/G ratio of 1.37 and a beta of 0.47. The business has a 50 day moving average of $19.16 and a 200-day moving average of $18.25. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $20.82.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). The business had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The business’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.29 earnings per share. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th were paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Wednesday, August 12th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s dividend payout ratio (DPR) is presently 96.55%.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.